Researchers will study changes in microRNAs in the blood of dogs enrolled in the Golden Retriever Lifetime Study and diagnosed with hemangiosarcoma to identify early disease biomarkers.

SUMMARY: Researchers will evaluate an innovative approach using engineered intracellular bacteria called quasiorganelles as a platform for the intracellular delivery of proteins to histiocytic sarcoma cells and surrounding immune cells in the local tumor environment. This proteins have been selected to suppress cancer growth and stimulate the immune system for the purpose of eliminating cancer cells.

SUMMARY: Researchers will investigate whether their newly developed urine testing method, Raman molecular urinalysis (RMU), can detect signs of hemangiosarcoma (HSA).

Researchers will study the cellular landscape of soft-tissue sarcomas in dogs to identify novel therapy targets.    

Researchers will search for new therapy targets for hemangiosarcoma in dogs to inform the development of much-needed therapies and preventives for this deadly cancer.

This study evaluates a new therapeutic agent designed to inhibit the survivin protein in canine lymphoma.

Researchers will develop early detection and prevention strategies for dogs with diffuse large B-cell lymphoma.

Researchers will assess the value of a genetic prognostic tool to assist with treatment decisions for dogs with diffuse large B-cell lymphoma.